Medpace Holdings, Inc. $MEDP Stock Sold by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 3.7% during the third quarter, HoldingsChannel reports. The firm owned 178,716 shares of the company’s stock after selling 6,806 shares during the period. Medpace makes up approximately 1.2% of Stephens Investment Management Group LLC’s holdings, making the stock its 16th biggest holding. Stephens Investment Management Group LLC’s holdings in Medpace were worth $111,551,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in MEDP. Aberdeen Group plc raised its holdings in shares of Medpace by 5,119.5% during the 3rd quarter. Aberdeen Group plc now owns 2,231,252 shares of the company’s stock valued at $1,392,703,000 after buying an additional 2,188,504 shares in the last quarter. BlackRock Inc. bought a new stake in Medpace in the 2nd quarter worth approximately $1,323,047,000. State Street Corp lifted its position in Medpace by 4.2% in the 2nd quarter. State Street Corp now owns 710,895 shares of the company’s stock worth $376,483,000 after buying an additional 28,666 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Medpace by 8.3% in the first quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock worth $242,337,000 after buying an additional 38,760 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Medpace by 5.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 395,769 shares of the company’s stock worth $190,044,000 after buying an additional 20,736 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on MEDP. TD Cowen increased their price target on shares of Medpace from $492.00 to $673.00 and gave the company a “hold” rating in a research report on Friday, October 23rd. Truist Financial boosted their price objective on shares of Medpace from $609.00 to $633.00 and gave the stock a “hold” rating in a report on Friday, October 23rd. Barclays boosted their price objective on shares of Medpace from $625.00 to $675.00 and gave the stock an “equal weight” rating in a report on Friday, October 23rd. Mizuho set a $730.00 target price on shares of Medpace in a report on Friday, October 23rd. Finally, Weiss Ratings upgraded shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $649.27.

View Our Latest Research Report on MEDP

Insider Activity

In related news, VP Susan E. Burwig sold 3,940 shares of Medpace stock in a transaction on Tuesday, October 27th. The shares were sold at an average price of $677.00, for a total value of $2,667,380.00. Following the transaction, the vice president directly owned 54,012 shares of the company’s stock, valued at $36,566,124. The trade was a 6.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Stephen P. Ewald sold 1,245 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $690.00, for a total transaction of $859,050.00. Following the sale, the general counsel owned 19,098 shares of the company’s stock, valued at $13,177,620. This represents a 6.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 248,073 shares of company stock valued at $155,909,483. 20.50% of the stock is currently owned by company insiders.

Medpace Trading Up 0.6%

NASDAQ MEDP opened at $650.50 on Thursday. The firm has a market cap of $18.19 billion, a PE ratio of 35.84, a price-to-earnings-growth ratio of 2.53 and a beta of 1.12. Medpace Holdings, Inc. has a 1-year low of $373.00 and a 1-year high of $693.97. The stock has a 50-day moving average of $633.11 and a 200-day moving average of $534.67.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.44 by $0.40. The business had revenue of $716.00 million for the quarter, compared to analyst estimates of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. Medpace’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company earned $3.86 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.

About Medpace

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.